13F Holdings
中文EN

SPRC SciSparc Ltd. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1611746 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-54.6%
TTM net income YoY-22.7%
TTM EPS YoY-91.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin38.7%
Operating margin-560.2%
Net margin-481.2%
FCF margin—
EBITDA margin-523.3%

Returns

ROE-79.7%
ROA-58.4%
ROIC (approx.)-95.1%
Asset turnover0.12x

Leverage & solvency

Liabilities / assets13.6%
Debt / equity0.00x
Current ratio5.36x
Interest coverage-20.73x

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-11.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2018Q2*2018-06-302017Q2*2017-06-30
Income statement
Revenue——
R&D expense$650,000$455,000
SG&A expense$1.00M$971,000
Operating income-$1.65M-$1.43M
Interest expense$1,000$437,000
Net income-$1.21M-$1.86M
EBITDA-$1.65M-$1.43M
EPS (basic)0.010.03
EPS (diluted)0.010.03
Balance sheet
Cash & equivalents$5.10M$11.78M
Receivables$448,000$242,000
Current assets$6.28M$12.04M
PP&E, netmay include right-of-use assets (IFRS)$53,000$17,000
Total assets$6.38M$12.06M
Current liabilities$1.23M$671,000
Total liabilities$1.23M$671,000
Shareholders' equity$5.15M$11.38M
Cash flow statement
Operating cash flow-$1.83M-$1.90M
Capital expenditure$3,000$7,000
Free cash flow-$1.84M-$1.91M
Investing cash flow-$503,000-$9,000
Financing cash flow$1,000$1.94M
Depreciation & amortization$3,000$1,000
Stock-based compensation$138,000$71,000

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.